Since July 2016, and in line with the IPHA Code of Practice for the Pharmaceutical Industry, companies have disclosed financial transfers of value (ToV)—whether direct or […]
Professor Michael Barry of the National Centre for Pharmacoeconomics made a number of unbalanced assertions on RTE Radio 1 last Sunday regarding suppliers of orphan medicines […]
Towards a Collaborative European Approach: Industry perspectives on access, innovation and coordination Joint statement from innovative pharmaceutical industry associations in the BeNeLuxA countries The national trade […]
The Irish Pharmaceutical Healthcare Association (IPHA) today welcomed encouraging growth in clinical trial activity in Ireland, while highlighting that system reforms are needed to ensure the […]
The access timelines for rare disease medicines have increased to 801 days from 685 days as reported last year. Average access timelines for all medicines […]
A new report shows Ireland’s pharmaceutical sector is of unprecedented economic importance and national strategic value. Conclusion of IPHA Framework Agreement is a new direction […]
New four-year deal designed to deliver faster patient access to innovative medicines, within 180 days to HSE decisions on reimbursement and a stable policy framework. […]
6,000 patients could benefit from €30 million for new medicines announced in Budget 2026 Minister’s commitment to adhering to the legislative timelines for new medicines decisions […]
